Intellia Therapeutics Inc (NASDAQ:NTLA) traded down 8.9% during trading on Friday . The company traded as low as $23.09 and last traded at $21.12. 554,973 shares were traded during trading, a decline of 42% from the average session volume of 960,375 shares. The stock had previously closed at $23.19.
A number of equities research analysts have commented on the stock. Jefferies Group set a $42.00 target price on shares of Intellia Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, October 31st. Oppenheimer restated a “hold” rating on shares of Intellia Therapeutics in a research note on Monday, December 18th. BidaskClub upgraded shares of Intellia Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, December 29th. ValuEngine cut shares of Intellia Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, November 15th. Finally, Leerink Swann raised their target price on shares of Intellia Therapeutics from $29.00 to $37.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 31st. They noted that the move was a valuation call. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $30.17.
The firm has a market cap of $925.60, a PE ratio of -14.19 and a beta of 3.60.
Several hedge funds have recently bought and sold shares of NTLA. Nationwide Fund Advisors grew its holdings in shares of Intellia Therapeutics by 117.7% in the second quarter. Nationwide Fund Advisors now owns 8,048 shares of the company’s stock valued at $129,000 after purchasing an additional 4,351 shares in the last quarter. Dynamic Technology Lab Private Ltd purchased a new position in shares of Intellia Therapeutics in the second quarter valued at $167,000. Virtu KCG Holdings LLC purchased a new position in shares of Intellia Therapeutics in the second quarter valued at $203,000. The Manufacturers Life Insurance Company grew its holdings in shares of Intellia Therapeutics by 451.2% in the second quarter. The Manufacturers Life Insurance Company now owns 13,224 shares of the company’s stock valued at $212,000 after purchasing an additional 10,825 shares in the last quarter. Finally, Fox Run Management L.L.C. purchased a new position in shares of Intellia Therapeutics in the fourth quarter valued at $230,000. 48.12% of the stock is owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY NOTICE: This piece was first reported by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright legislation. The correct version of this piece can be viewed at https://sportsperspectives.com/2018/02/09/intellia-therapeutics-ntla-trading-down-8-9.html.
About Intellia Therapeutics
Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.